
  
    
      
        Background_NNP
        Following_VBG a_DT classic_JJ epithelial-mesenchymal_JJ interaction_NN
        developmental_NN program_NN ,_, the_DT mouse_NN neonatal_NN submandibular_NN
        salivary_JJ gland_NN (_( SMG_NNP )_) is_VBZ comprised_VBN of_IN large_JJ and_CC small_JJ ducts_NNS
        which_WDT terminate_VB in_IN lumen-containing_JJ ,_, presumptive_JJ acini_NN that_WDT
        express_VBP embryonic_JJ mucin_NN [_NN 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD ]_NN ._. Progressive_JJ
        prenatal_NN morphogenesis_NNS begins_VBZ as_IN a_DT solid_JJ outgrowth_NN from_IN the_DT
        oral_JJ epithelium_NN around_IN E_NNP 11_CD ._. 5_LS ,_, and_CC is_VBZ best_JJS conceptualized_JJ in_IN
        stages_NNS [_NN 9_CD ]_NN :_: 
        Initial_JJ Bud_NNP ,_, Pseudoglandular_NNP ,_,
        Canalicular_NNP ,_, and_CC 
        Terminal_NNP Bud_NNP ._. Epithelial_NNP cell_NN
        proliferation_NN is_VBZ found_VBN in_IN all_DT stages_NNS ,_, even_RB after_IN
        well-defined_JJ lumen_NN formation_NN in_IN the_DT 
        Terminal_NNP Bud_NNP Stage_NNP ._. Epithelial_NNP cell_NN
        apoptosis_NNS begins_VBZ with_IN the_DT onset_NN of_IN lumen_NN formation_NN in_IN the_DT 
        Canalicular_NNP Stage_NNP ._.
        The_DT proper_JJ balance_NN between_IN SMG_NNP epithelial_NN cell_NN
        proliferation_NN ,_, quiescence_NN ,_, and_CC apoptosis_NNS is_VBZ mediated_JJ by_IN the_DT
        appearance_NN of_IN transcription_NN factors_NNS ,_, growth_NN factors_NNS ,_,
        cytokines_NNS ,_, caspases_NNS ,_, etc_FW ._. at_IN specific_JJ times_NNS and_CC places_NNS [_NN 10_CD
        11_CD 12_CD 13_CD 14_CD ]_NN ._. These_DT SMG_NNP cellular_JJ and_CC extracellular_NN
        components_NNS may_MD be_VB visualized_JJ as_IN a_DT 
        Connections_NNP Map_NNP which_WDT details_NNS the_DT
        functional_JJ relationships_NNS within_IN and_CC between_IN pathways_NNS (_( Fig_NNP ._.
        1_LS )_) ._.
        Complex_JJ networks_NNS of_IN biological_JJ signaling_VBG pathways_NNS (_( Fig_NNP ._.
        1_LS )_) emerge_VB from_IN the_DT interconnections_NNS of_IN simple_JJ pathways_NNS
        under_IN local_JJ control_NN [_NN 15_CD 16_CD 17_CD ]_NN ._. As_IN such_JJ ,_, these_DT cellular_JJ
        pathways_NNS are_VBP more_RBR analogous_JJ to_TO the_DT mostly_RB redundant_JJ ,_,
        overlapping_VBG neural_NN network_NN of_IN the_DT brain_NN than_IN to_TO traffic_NN
        grids_NNS of_IN intersecting_VBG streets_NNS and_CC interacting_VBG vehicles_NNS ._.
        There_EX are_VBP two_CD general_JJ ,_, not_RB mutually_RB exclusive_JJ ,_, classes_NNS of_IN
        interconnections_NNS :_: (_( 1_LS )_) junctions_NNS which_WDT serve_VBP as_IN signal_NN
        integrators_NNS and_CC (_( 2_LS )_) nodes_NNS which_WDT split_NN the_DT signal_NN and_CC route_NN
        them_PRP to_TO multiple_JJ outputs_NNS [_NN 18_CD ]_NN ._. Understanding_NNP the_DT
        nonlinear_NN dynamics_NNS of_IN these_DT interconnections_NNS is_VBZ intrinsic_JJ
        to_TO understanding_VBG the_DT regulation_NN of_IN SMG_NNP morphogenesis_NNS ._. This_DT
        requires_VBZ the_DT integration_NN of_IN transcriptomic_JJ ,_, proteomic_JJ ,_,
        phenomic_JJ ,_, and_CC bioinformatic_JJ approaches_NNS ,_, not_RB least_JJS because_IN
        development_NN ,_, in_IN its_PRP$ most_RBS basic_JJ sense_NN ,_, is_VBZ genes_NNS plus_CC context_NN
        [_NN 19_CD 20_CD 21_CD 22_CD ]_NN ._.
        With_IN the_DT present_JJ experiments_NNS ,_, we_PRP sought_VBD a_DT glimpse_NN of_IN the_DT
        extraordinarily_RB complex_JJ behaviors_NNS of_IN a_DT focused_VBN signaling_VBG
        network_NN (_( Fig_NNP ._. 1_LS )_) ._. To_TO this_DT end_NN ,_, we_PRP studied_VBD the_DT molecular_JJ
        patterns_NNS and_CC phenotypic_JJ outcomes_NNS of_IN a_DT nodal_NN "_'' short_JJ
        circuit_NN "_'' ,_, i_NNP ._. e_SYM ._. ,_, the_DT inhibition_NN of_IN NF-κB_NNP activation_NN and_CC
        translocation_NN to_TO the_DT nucleus_NN to_TO bind_NN to_TO NF-κB_NNP response_NN
        genes_NNS ._. In_IN most_JJS cell_NN types_NNS ,_, the_DT NF-κB_NNP p_NN 50_CD /_NN p_NN 65_CD heterodimer_NN is_VBZ
        maintained_VBN as_IN an_DT inactive_JJ form_NN in_IN the_DT cytoplasm_NN bound_VBN to_TO
        the_DT inhibitory_NN protein_NN IκB_NNP ._. Exposure_NNP of_IN cells_NNS to_TO stimuli_NNS of_IN
        NF-κB_NNP induces_VBZ the_DT rapid_JJ phosphorylation_NN and_CC subsequent_JJ
        degradation_NN of_IN IκB_NNP proteins_NNS ._. Released_NNP NF-κB_NNP dimers_NNS then_RB
        translocate_NN to_TO the_DT nucleus_NN ,_, bind_NN to_TO its_PRP$ cognate_NN DNA_NNP
        elements_NNS ,_, and_CC induce_VB the_DT expression_NN of_IN target_NN genes_NNS [_NN 23_CD 24_CD
        25_CD ]_NN ._. Activated_NNP ,_, nuclear_JJ translocated_JJ ,_, NF-κB_NNP transcription_NN
        factor_NN has_VBZ been_VBN documented_VBN in_IN the_DT mouse_NN embryo_NN from_IN the_DT
        1_CD -_: cell_NN stage_NN onward_NN [_NN 26_CD 27_CD ]_NN ._. Activated_NNP NF-κB_NNP
        translocation_NN into_IN the_DT nucleus_NN ,_, directly_RB or_CC indirectly_RB ,_,
        effects_VBZ the_DT transcriptional_NN control_NN of_IN over_IN 150_CD target_NN
        genes_NNS [_NN 28_CD ]_NN ._. NF-κB_NNP enhances_VBZ cell_NN proliferation_NN by_IN
        stimulating_VBG the_DT expression_NN of_IN cytokines_NNS such_JJ as_IN TNF_NNP ,_, IL-_NNP 1_CD ,_,
        IL-_NNP 2_CD ,_, IL-_NNP 6_CD ,_, and_CC IL-_NNP 8_CD ,_, among_IN others_NNS [_NN 28_CD 29_CD ]_NN ;_: NF-κB_NNP
        inhibits_NNS apoptosis_NNS by_IN inducing_VBG TRAF_NNP and_CC clAP_NN expression_NN
        which_WDT suppresses_NNS Caspase_NNP 8_CD activation_NN [_NN 30_CD ]_NN ,_, and_CC by_IN
        inhibition_NN of_IN p_NN 53_CD transactivation_NN [_NN 31_CD 32_CD ]_NN ._.
        We_PRP interrupted_VBN the_DT NF-κB_NNP signal_NN in_IN embryonic_JJ SMG_NNP
        explants_NNS using_VBG the_DT cell-permeable_JJ peptide_NN SN_NNP 50_CD ,_, a_DT potent_JJ
        inhibitor_NN of_IN NF-κB_NNP nuclear_JJ translocation_NN [_NN 25_CD 26_CD ]_NN ,_, [_NN 33_CD
        34_CD 35_CD ]_NN ._. SN_NNP 50_CD -_: mediated_JJ inhibition_NN of_IN NF-κB_NNP nuclear_JJ
        translocation_NN in_IN SMG_NNP explants_NNS results_NNS in_IN extensive_JJ
        apoptosis_NNS and_CC a_DT very_RB substantial_JJ decline_NN in_IN cell_NN
        proliferation_NN ._. Functional_NNP genomic_JJ analyses_NNS demonstrate_VBP that_DT
        inhibition_NN of_IN NF-κB_NNP signaling_VBG is_VBZ associated_VBN with_IN the_DT
        altered_VBN expression_NN of_IN numerous_JJ components_NNS of_IN the_DT genetic_JJ
        network_NN of_IN related_VBN signaling_VBG pathways_NNS ._. This_DT modified_VBN
        expression_NN of_IN genes_NNS and_CC proteins_NNS associated_VBN with_IN the_DT
        inhibition_NN of_IN the_DT cell_NN cycle_NN and_CC the_DT induction_NN of_IN
        apoptosis_NNS ,_, as_RB well_RB as_IN the_DT increased_VBN activation_NN of_IN
        proapoptotic_JJ and_CC compensatory_JJ antiapoptotic_JJ pathways_NNS ,_,
        provides_VBZ a_DT "_'' snapshot_NN "_'' of_IN the_DT broad_JJ primary_JJ and_CC secondary_JJ
        effects_NNS of_IN NF-κB_NNP signaling_VBG during_IN SMG_NNP development_NN ._.
      
      
        Results_NNS and_CC discussion_NN
        
          NF-κB_NNP inhibition_NN and_CC SMG_NNP phenotype_NN
          E_NNP 15_CD SMG_NNP primordia_NN were_VBD cultured_JJ for_IN 2_CD days_NNS in_IN the_DT
          presence_NN or_CC absence_NN of_IN the_DT cell-permeable_JJ peptide_NN SN_NNP 50_CD ,_, a_DT
          potent_JJ inhibitor_NN of_IN NF-κB_NNP nuclear_JJ translocation_NN [_NN 33_CD 34_CD
          35_CD ]_NN ._. SN_NNP 50_CD is_VBZ composed_VBN of_IN a_DT nuclear_JJ localization_NN
          sequence_NN (_( NLS_NNP )_) for_IN NF-κB_NNP p_NN 50_CD linked_VBN to_TO a_DT cell-permeable_JJ
          carrier_NN [_NN 33_CD 34_CD 35_CD ]_NN ._. SN_NNP 50_CD blocks_NNS the_DT intracellular_NN
          recognition_NN mechanism_NN for_IN the_DT NLS_NNP on_IN NF-κB_NNP ,_, thus_RB
          inhibiting_VBG NF-κB_NNP 's_POS translocation_NN through_IN the_DT nuclear_JJ
          pore_NN ._. After_IN 2_CD days_NNS in_IN culture_NN ,_, SN_NNP 50_CD -_: treated_VBN explants_NNS
          exhibit_NN a_DT substantial_JJ decrease_NN in_IN gland_NN size_NN and_CC
          branching_VBG morphogenesis_NNS compared_VBN to_TO controls_NNS (_( compare_VB
          Fig_NNP ._. 3_LS Ato_NNP 3_CD B_NNP )_) ._. These_DT 2_CD -_: day_NN SN_NNP 50_CD -_: treated_VBN explants_NNS
          demonstrate_VBP a_DT highly_RB significant_JJ 81_CD %_NN decline_NN (_( t_NN 
          4_CD =_SYM 26_CD ._. 25_CD ;_: p_NN <_NN 0_CD ._. 001_CD )_) in_IN cell_NN
          proliferation_NN (_( Fig_NNP ._. 3_LS A_DT ,_, B_NNP ;_: Fig_NNP ._. 4_LS A_DT )_) and_CC a_DT significant_JJ
          10_CD -_: fold_VB increase_NN (_( t_NN 
          4_CD =_SYM 7_CD ._. 98_CD ;_: p_NN <_NN 0_CD ._. 001_CD )_) in_IN apoptosis_NNS
          (_( Fig_NNP ._. 3_LS C_NNP ,_, D_NNP ;_: Fig_NNP ._. 4_LS B_NNP )_) ._. This_DT substantial_JJ increase_NN in_IN
          apoptosis_NNS is_VBZ associated_VBN with_IN a_DT highly_RB significant_JJ >_NN
          4_CD -_: fold_VB increase_NN (_( t_NN 
          4_CD =_SYM 22_CD ._. 66_CD ;_: p_NN <_NN 0_CD ._. 001_CD )_) in_IN 
          activated_VBN (_( phosphorylated_JJ )_) p_NN 53_CD
          (_( Fig_NNP ._. 5_LS )_) ._. This_DT result_NN is_VBZ not_RB surprising_JJ ,_, given_VBN that_IN NF-κB_NNP
          inactivates_NNS p_NN 53_CD [_NN 32_CD ]_NN ._.
          To_TO demonstrate_VB that_IN this_DT SN_NNP 50_CD phenotype_NN is_VBZ consequent_JJ
          to_TO SN_NNP 50_CD -_: mediated_JJ inhibition_NN of_IN NF-κB_NNP nuclear_JJ
          translocation_NN and_CC not_RB the_DT nonspecific_JJ effect_NN of_IN exogenous_JJ
          peptide_NN ,_, we_PRP compared_VBD E_NNP 15_CD +_NN 2_CD SMG_NNP phenotypes_NNS in_IN explants_NNS
          cultured_JJ in_IN control_NN media_NNS ,_, 100_CD μg_NN /_NN ml_NN SN_NNP 50_CD peptide_NN ,_, or_CC 100_CD
          μg_NN /_NN ml_NN mutant_JJ SN_NNP 50_CD (_( mSN_NN 50_CD )_) peptide_NN ._. As_IN expected_VBN ,_, we_PRP found_VBD
          a_DT marked_VBN difference_NN between_IN control_NN and_CC SN_NNP 50_CD -_: treated_VBN SMGs_NNP
          but_CC none_NN between_IN control_NN and_CC mutant_JJ peptide-treated_JJ
          explants_NNS (_( data_NNS not_RB shown_VBN )_) ._. In_IN addition_NN ,_, since_IN TNF_NNP /_NN TNFR_NNP 1_CD
          signaling_VBG has_VBZ been_VBN shown_VBN to_TO induce_VB embryonic_JJ SMG_NNP cell_NN
          proliferation_NN and_CC inhibit_VB apoptosis_NNS 
          in_IN vitro_NN [_NN 13_CD ]_NN and_CC TNF_NNP /_NN TNFR_NNP 1_CD
          signal_NN transduction_NN primarily_RB signals_VBZ by_IN induction_NN of_IN
          NF-κB_NNP nuclear_JJ translocation_NN [_NN 36_CD ]_NN ,_, we_PRP postulated_JJ that_IN
          TNF_NNP supplementation_NN should_MD have_VB no_DT inductive_JJ effect_NN on_IN
          SN_NNP 50_CD -_: treated_VBN SMGs_NNP ._. Thus_RB ,_, we_PRP cultured_JJ E_NNP 15_CD control_NN ,_,
          SN_NNP 50_CD -_: treated_VBN ,_, and_CC mSN_NN 50_CD -_: treated_VBN explants_NNS in_IN the_DT presence_NN
          of_IN TNF_NNP (_( rTNF_NN ,_, 10_CD U_NNP /_NN ml_NN )_) supplementation_NN for_IN 4_CD or_CC more_JJR
          days_NNS ._. In_IN this_DT set_JJ of_IN experiments_NNS ,_, we_PRP extended_VBD the_DT culture_NN
          period_NN to_TO provide_VB sufficient_JJ time_NN to_TO allow_VB for_IN possible_JJ
          TNF-mediated_NNP recovery_NN ._. TNF_NNP supplementation_NN induced_VBD NF-κB_NNP
          (_( p_NN 50_CD and_CC p_NN 65_CD )_) translocation_NN (_( Fig_NNP ._. 6_CD A_DT )_) ,_, a_DT marked_VBN increase_NN
          in_IN explant_NN size_NN ,_, and_CC a_DT notable_JJ increase_NN in_IN cell_NN
          proliferation_NN (_( not_RB shown_VBN )_) ;_: similar_JJ results_NNS were_VBD seen_VBN in_IN
          TNF_NNP +_NN mSN_NN 50_CD -_: treated_VBN explants_NNS (_( not_RB shown_VBN )_) ._. By_IN contrast_NN ,_,
          NF-κB_NNP redistribution_NN was_VBD not_RB found_VBN in_IN explants_NNS cultured_JJ
          in_IN TNF_NNP +_NN SN_NNP 50_CD (_( Fig_NNP ._. 6_CD B_NNP )_) ;_: rather_RB ,_, NF-κB_NNP was_VBD absent_JJ from_IN
          epithelial_NN cell_NN nuclei_NN and_CC exhibited_VBN a_DT very_RB weak_JJ ,_, diffuse_NN
          cytoplasmic_JJ distribution_NN ._. Moreover_RB ,_, TNF_NNP supplementation_NN
          was_VBD unable_JJ to_TO rescue_VB the_DT abnormal_JJ SN_NNP 50_CD phenotype_NN ._.
          Finally_RB ,_, the_DT identical_JJ response_NN of_IN control_NN and_CC
          mSN_NN 50_CD -_: treated_VBN SMG_NNP explants_NNS to_TO TNF_NNP supplementation_NN
          provides_VBZ further_JJ evidence_NN that_IN this_DT mutant_JJ peptide_NN had_VBD no_DT
          effect_NN on_IN NF-κB_NNP activation_NN ._.
        
        
          Transcriptomic_NNP analysis_NN
          To_TO investigate_VB transcriptional_NN responses_NNS to_TO NF-κB_NNP
          inhibition_NN ,_, we_PRP analyzed_VBD control_NN and_CC SN_NNP 50_CD -_: treated_VBN E_NNP 15_CD +_NN 2_CD
          SMG_NNP explants_NNS using_VBG cDNA_NN arrays_NNS ._. Of_IN the_DT 1176_CD transcripts_NNS
          assayed_JJ on_IN these_DT arrays_NNS (_( including_VBG transcription_NN factors_NNS ,_,
          cell_NN cycle_NN regulators_NNS ,_, growth_NN factors_NNS ,_, etc_FW ._. )_) ,_, 691_CD (_( ~_NN 60_CD %_NN )_)
          demonstrated_VBD a_DT 1_CD ._. 5_CD -_: fold_VB or_CC greater_JJR increase_NN or_CC decrease_VB
          in_IN expression_NN with_IN SN_NNP 50_CD -_: induced_VBN NF-κB_NNP inhibition_NN (_( Fig_NNP ._.
          7_CD )_) ._. Of_IN these_DT ,_, we_PRP focused_VBD our_PRP$ attention_NN on_IN those_DT signal_NN
          transduction_NN ,_, cell_NN cycle_NN ,_, and_CC apoptosis_NNS transcripts_NNS
          related_VBN to_TO the_DT 
          Connections_NNP Map_NNP (_( Fig_NNP ._. 1_LS )_) ._. With_IN
          inhibition_NN of_IN NF-κB_NNP translocation_NN into_IN the_DT nucleus_NN ,_, 53_CD 
          Connections_NNP Map_NNP transcripts_NNS exhibit_NN
          altered_VBD expression_NN (_( Table_NNP 1_LS )_) ._. We_PRP used_VBD Probabilistic_NNP
          Neural_NNP Network_NNP (_( PNN_NNP )_) analyses_NNS to_TO determine_VB which_WDT
          transcript_NN changes_NNS best_JJS discriminate_JJ control_NN from_IN
          SN_NNP 50_CD -_: treated_VBN explants_NNS ._. These_DT analyses_NNS identified_VBD those_DT
          transcripts_NNS with_IN significant_JJ changes_NNS which_WDT are_VBP relatively_RB
          more_RBR important_JJ in_IN defining_VBG the_DT SMG_NNP phenotype_NN ,_, regardless_RB
          of_IN the_DT direction_NN (_( up_RB or_CC down_RB )_) of_IN change_NN ._.
          Among_IN the_DT cell_NN cycle_NN transcripts_NNS with_IN altered_VBN
          expression_NN (_( Fig_NNP ._. 8_CD A_DT )_) ,_, PNN_NNP analysis_NN shows_VBZ that_IN the_DT 
          increased_VBN expression_NN of_IN cyclin_NN D_NNP 2_CD ,_,
          p_NN 57_CD ,_, and_CC Cdc_NNP 25_CD a_DT ,_, as_RB well_RB as_IN 
          decreased_VBN expression_NN of_IN PCNA_NNP ,_, best_JJS
          discriminate_JJ control_NN from_IN SN_NNP 50_CD -_: treated_VBN explants_NNS ._. Cyclin_NNP
          D_NNP 2_CD ,_, Cdc_NNP 25_CD a_DT ,_, and_CC PCNA_NNP promote_VBP cell_NN division_NN ;_: p_NN 57_CD inhibits_NNS
          cell_NN division_NN (_( Fig_NNP ._. 1_LS )_) ._. The_DT significant_JJ decline_NN in_IN PCNA_NNP
          transcript_NN (_( Table_NNP 1_LS )_) is_VBZ consistent_JJ with_IN the_DT highly_RB
          significant_JJ (_( p_NN <_NN 0_CD ._. 001_CD )_) decline_NN in_IN PCNA-defined_NNP cell_NN
          proliferation_NN (_( Fig_NNP ._. 4_LS A_DT )_) ._.
          Among_IN apoptosis_NNS transcripts_NNS with_IN altered_VBN expression_NN
          (_( Fig_NNP ._. 8_CD B_NNP )_) ,_, PNN_NNP analysis_NN demonstrates_VBZ that_IN downregulated_JJ
          Caspase_NNP 1_CD transcript_NN ,_, almost_RB alone_RB ,_, best_JJS discriminates_NNS
          control_VBP from_IN SN_NNP 50_CD -_: treated_VBN explants_NNS ._. Caspase_NNP 1_CD activates_NNS
          Caspase_NNP 3_CD and_CC appears_VBZ to_TO promote_VB production_NN of_IN the_DT
          cytokine_NN IL-_NNP 1_CD β_NN ,_, which_WDT upregulates_NNS the_DT transcription_NN of_IN
          both_DT Caspases_NNP 1_CD and_CC 3_CD ,_, additionally_RB potentiating_VBG
          apoptosis_NNS [_NN 37_CD 38_CD ]_NN ._. Thus_RB ,_, 
          this_DT regulatory_JJ mechanism_NN of_IN
          caspase_NN gene_NN expression_NN would_MD likely_RB be_VB diminished_VBN in_IN
          SN_NNP 50_CD -_: treated_VBN explants_NNS were_VBD they_PRP allowed_VBD to_TO develop_VB
          further_RB in_IN culture_NN ._. Contemporaneous_NNP proteome_NN analysis_NN
          provides_VBZ a_DT very_RB different_JJ profile_NN (_( see_VB Table_NNP 2_CD and_CC text_NN
          below_IN )_) ._.
          Although_IN many_JJ "_'' Ras_NNP /_NN Raf_NNP "_'' growth_NN factor_NN pathway_NN
          transcripts_NNS were_VBD upregulated_JJ (_( Table_NNP 1_LS )_) ,_, as_IN a_DT group_NN they_PRP
          were_VBD poor_JJ predictors_NNS of_IN SMG_NNP phenotype_NN (_( control_NN v_NN ._.
          SN_NNP 50_CD -_: treated_VBN )_) ._. PNN_NNP analysis_NN (_( Fig_NNP ._. 9_CD A_DT )_) shows_VBZ that_IN only_RB
          IGF_NNP 2_CD ,_, IGF_NNP 2_CD R_NN ,_, and_CC IGFBP_NNP 3_CD are_VBP best_JJS at_IN discriminating_VBG
          control_NN from_IN SN_NNP 50_CD -_: treated_VBN explants_NNS ._.
          TGF-β_NNP 1_CD and_CC TGF-β_NNP 2_CD show_NN a_DT 2_CD -_: fold_VB increase_NN (_( Table_NNP 1_LS )_)
          which_WDT is_VBZ not_RB unexpected_JJ given_VBN that_IN TGF-β_NNP and_CC NF-κB_NNP are_VBP
          found_VBN to_TO be_VB inversely_RB proportional_JJ to_TO one_CD another_DT [_NN 39_CD ]_NN
          ._. Nevertheless_RB ,_, among_IN the_DT TGF-β_NNP family_NN transcripts_NNS and_CC
          others_NNS related_VBN to_TO their_PRP$ expression_NN and_CC signal_NN
          transduction_NN (_( Fig_NNP ._. 9_CD B_NNP )_) ,_, BMP_NN 1_CD ,_, BMP_NN 3_CD b_SYM ,_, BMP_NN 8_CD a_DT ,_, Smad_NNP 7_CD ,_, and_CC GR_NNP
          best_JJS discriminate_JJ control_NN from_IN SN_NNP 50_CD -_: treated_VBN explants_NNS ._.
          BMPs_NNP inhibit_VB cell_NN proliferation_NN via_IN downstream_JJ Smad_NNP 1_CD /_NN 5_CD /_NN 8_CD
          proteins_NNS whereas_IN Smad_NNP 7_CD inhibits_NNS TGF-β_NNP and_CC activin_NN
          signaling_VBG (_( Fig_NNP ._. 1_LS )_) ._. This_DT inhibition_NN of_IN TGF-β_NNP /_NN activin_NN
          signaling_VBG is_VBZ modulated_JJ through_IN NF-κB-dependent_NNP inhibition_NN
          of_IN Smad_NNP 7_CD [_NN 40_CD ]_NN ._. In_IN addition_NN ,_, there_EX is_VBZ a_DT negative_JJ
          feedback_NN between_IN NF-κB_NNP and_CC Smad_NNP 7_CD ;_: activated_VBN NF-κB_NNP
          inhibits_NNS Smad_NNP 7_CD promotor_NN activity_NN [_NN 41_CD ]_NN whereas_IN Smad_NNP 7_CD
          inhibits_NNS NF-κB_NNP activation_NN and_CC potentiates_NNS apoptosis_NNS [_NN 42_CD
          ]_NN ._. Curiously_RB ,_, the_DT 
          relative_JJ importance_NN of_IN increased_VBN
          Smad_NNP 7_CD expression_NN is_VBZ 20_CD times_NNS greater_JJR than_IN that_DT of_IN Smad_NNP 1_CD /_NN 5_CD
          
          vis_FW ._. defining_VBG the_DT NF-κB-inhibited_NNP
          explants_NNS ._. It_PRP is_VBZ likely_JJ that_IN ,_, in_IN the_DT absence_NN of_IN NF-κB_NNP 's_POS
          negative_JJ regulation_NN ,_, Smad_NNP 7_CD signaling_VBG is_VBZ upregulated_JJ ,_,
          thereby_RB sensitizing_VBG cells_NNS to_TO apoptosis_NNS ._. Finally_RB ,_, the_DT
          nearly_RB 2_CD -_: fold_VB decrease_VB in_IN glucocorticoid_NN receptor_NN (_( GR_NNP )_) is_VBZ
          also_RB of_IN high_JJ relative_JJ importance_NN in_IN defining_VBG the_DT
          SN_NNP 50_CD -_: treated_VBN phenotype_NN (_( Table_NNP 1_LS )_) ._. Glucocorticoids_NNP (_( CORT_NNP )_)
          function_NN through_IN the_DT GR_NNP to_TO both_DT activate_VBP specific_JJ gene_NN
          expression_NN as_RB well_RB as_IN transrepress_NNS NF-κB_NNP [_NN 41_CD ]_NN ._. Since_IN
          GR_NNP confers_VBZ this_DT latter_JJ effect_NN by_IN associating_VBG through_IN
          protein-protein_JJ interactions_NNS with_IN NF-κB_NNP bound_VBN at_IN κB_NN
          response_NN elements_NNS [_NN 43_CD 44_CD 45_CD 46_CD 47_CD ]_NN ,_, it_PRP is_VBZ important_JJ to_TO
          also_RB evaluate_VB changes_NNS in_IN GR_NNP protein_NN levels_NNS (_( see_VB
          below_IN )_) ._.
          Further_RB ,_, we_PRP utilized_JJ PNN_NNP analysis_NN to_TO determine_VB the_DT
          iterated_JJ composite_JJ relative_JJ importance_NN among_IN 
          Connections_NNP Map_NNP (_( Fig_NNP ._. 1_LS )_)
          transcripts_NNS which_WDT have_VBP altered_VBN expression_NN as_IN a_DT
          consequence_NN of_IN inhibition_NN of_IN NF-κB_NNP translocation_NN into_IN the_DT
          nucleus_NN (_( Fig_NNP ._. 10_CD )_) ._. That_DT is_VBZ ,_, we_PRP then_RB subjected_VBN those_DT
          transcripts_NNS with_IN altered_VBN expression_NN in_IN each_DT group_NN (_( cell_NN
          cycle_NN ,_, apoptosis_NNS ,_, Ras_NNP /_NN Raf_NNP ,_, TGF-β_NNP family_NN )_) previously_RB shown_VBN
          in_IN Figures_NNS 7_CD and_CC 8_CD to_TO be_VB relatively_RB important_JJ in_IN defining_VBG
          the_DT SN_NNP 50_CD SMG_NNP phenotype_NN to_TO further_VB PNN_NNP analysis_NN ._. This_DT
          transciptomic_JJ analysis_NN is_VBZ a_DT time-bound_JJ "_'' snapshot_NN "_'' in_IN
          which_WDT gene_NN expression_NN is_VBZ indicative_JJ of_IN possible_JJ future_JJ
          protein_NN expression_NN ._. It_PRP is_VBZ instructive_JJ that_IN ,_, of_IN the_DT 53_CD 
          Connections_NNP Map_NNP transcripts_NNS with_IN
          altered_VBN expression_NN (_( Table_NNP 1_LS )_) ,_, 4_CD genes_NNS of_IN diverse_JJ pathways_NNS
          but_CC overlapping_VBG function_NN best_JJS discriminate_JJ control_NN from_IN
          SN_NNP 50_CD -_: treated_VBN explants_NNS :_: PCNA_NNP ,_, GR_NNP ,_, BMP_NN 1_CD ,_, BMP_NN 3_CD b_SYM ._. The_DT
          declining_VBG PCNA_NNP and_CC GR_NNP reflect_VBP the_DT sharp_JJ decline_NN in_IN cell_NN
          proliferation_NN and_CC branching_VBG ;_: the_DT increasing_VBG BMP_NN 1_CD and_CC
          BMP_NN 3_CD b_SYM similarly_RB reflects_VBZ inhibition_NN of_IN cell_NN proliferation_NN
          (_( Fig_NNP ._. 1_LS )_) ._.
        
        
          Proteomic_NNP analysis_NN
          Our_PRP$ cDNA_NN array_NN analysis_NN provides_VBZ a_DT 
          good_JJ first_JJ approximation_NN of_IN 
          likely_JJ protein_NN differences_NNS ._.
          However_RB ,_, one_CD cannot_NN extrapolate_NN from_IN mRNA_NN abundance_NN to_TO
          relevant_JJ protein_NN levels_NNS [_NN 48_CD ]_NN ._. A_DT recent_JJ study_NN by_IN
          Aebersole_NNP and_CC coworkers_NNS [_NN 48_CD ]_NN analyzing_VBG yeast_NN protein_NN
          and_CC mRNA_NN abundance_NN clearly_RB showed_VBD that_DT mRNA_NN transcript_NN
          levels_NNS are_VBP 
          poor_JJ predictors_NNS of_IN protein_NN
          expression_NN ._. They_PRP demonstrate_VBP that_IN some_DT genes_NNS with_IN
          comparable_JJ mRNA_NN levels_NNS exhibited_VBN a_DT 20_CD -_: fold_VB difference_NN in_IN
          their_PRP$ protein_NN expression_NN while_IN mRNA_NN levels_NNS of_IN comparable_JJ
          protein_NN expression_NN varied_VBD as_RB much_RB as_IN 30_CD -_: fold_VB ._.
          Thus_RB ,_, we_PRP next_RB analyzed_VBD SN_NNP 50_CD -_: treated_VBN and_CC control_NN E_NNP 15_CD +_NN
          2_CD SMG_NNP explants_NNS using_VBG 2_CD -_: D_NNP Western_NNP Multiprotein_NNP Arrays_NNP to_TO
          determine_VB protein_NN differences_NNS ._. This_DT technique_NN allows_VBZ for_IN
          the_DT densitometric_JJ analysis_NN of_IN about_IN 600_CD signal_NN
          transduction_NN and_CC other_JJ proteins_NNS simultaneously_RB in_IN each_DT
          independent_JJ sample_NN (_( Fig_NNP ._. 11_CD )_) ._. As_IN shown_VBN in_IN Table_NNP 2_CD ,_, we_PRP
          find_VBP 18_CD proteins_NNS which_WDT have_VBP both_DT a_DT 1_CD ._. 5_CD -_: fold_VB or_CC greater_JJR
          change_NN with_IN NF-κB_NNP inhibition_NN 
          and_CC are_VBP specifically_RB related_VBN to_TO the_DT
          
          Connections_NNP Map_NNP (_( Fig_NNP ._. 1_LS )_) ._. They_PRP
          include_VBP signal_NN transduction_NN ,_, cell_NN cycle_NN ,_, and_CC apoptosis_NNS
          proteins_NNS that_WDT are_VBP either_DT directly_RB or_CC indirectly_RB
          downstream_JJ from_IN activation_NN of_IN the_DT TNF_NNP ,_, IL-_NNP 6_CD ,_, EGF_NNP ,_, IGF_NNP ,_,
          and_CC FGF_NNP signaling_VBG pathways_NNS ._. The_DT significant_JJ decline_NN in_IN
          PCNA_NNP protein_NN (_( Table_NNP 2_LS )_) is_VBZ consistent_JJ with_IN the_DT significant_JJ
          decline_NN in_IN PCNA_NNP transcript_NN (_( Table_NNP 1_LS )_) and_CC PCNA-defined_NNP
          cell_NN proliferation_NN (_( Fig_NNP ._. 4_LS A_DT )_) ._.
          PNN_NNP analysis_NN shows_VBZ that_IN among_IN cell_NN cycle_NN proteins_NNS with_IN
          altered_VBN expression_NN (_( Fig_NNP ._. 12_CD A_DT )_) ,_, the_DT increased_VBN expression_NN
          of_IN Chk_NNP 1_CD ,_, Chk_NNP 2_CD ,_, and_CC E_NNP 2_CD F_NN 1_CD best_JJS discriminates_NNS control_VBP from_IN
          SN_NNP 50_CD -_: treated_VBN explants_NNS ._. Of_IN particular_JJ interest_NN is_VBZ E_NNP 2_CD F_NN 1_CD ._.
          Among_IN the_DT five_CD known_VBN mammalian_JJ E_NNP 2_CD Fs_NNP ,_, the_DT ability_NN to_TO
          induce_VB apoptosis_NNS is_VBZ unique_JJ to_TO E_NNP 2_CD F_NN 1_CD [_NN 49_CD ]_NN ._.
          Overexpression_NNP of_IN E_NNP 2_CD F_NN 1_CD in_IN several_JJ cell_NN lines_NNS results_NNS in_IN G_NNP
          
          2_LS arrest_NN ,_, as_RB well_RB as_IN apoptosis_NNS via_IN
          p_NN 53_CD -_: dependent_JJ and_CC p_NN 53_CD -_: independent_JJ pathways_NNS [_NN 50_CD 51_CD 52_CD ]_NN ._.
          The_DT presence_NN of_IN a_DT dysplastic_JJ SMG_NNP phenotype_NN in_IN 
          E_NNP 2_CD f_SYM 1_CD -_: /_NN -_: mice_NNS indicates_VBZ that_IN E_NNP 2_CD F_NN 1_CD
          plays_VBZ an_DT important_JJ role_NN during_IN SMG_NNP development_NN [_NN 53_CD ]_NN ._.
          Moreover_RB ,_, E_NNP 2_CD F_NN 1_CD overexpression_NN in_IN human_JJ salivary_JJ gland_NN
          (_( HSG_NNP )_) cells_NNS diverted_VBN these_DT cells_NNS into_IN an_DT apoptotic_JJ
          pathway_NN [_NN 54_CD ]_NN ._.
          Among_IN apoptosis_NNS proteins_NNS with_IN altered_VBN expression_NN (_( Fig_NNP ._.
          12_CD B_NNP )_) ,_, PNN_NNP analysis_NN demonstrates_VBZ that_WDT increased_VBN expression_NN
          of_IN FAF_NNP and_CC Caspase_NNP 6_CD best_JJS discriminates_NNS control_VBP from_IN
          SN_NNP 50_CD -_: treated_VBN explants_NNS ._. Caspase_NNP 6_CD is_VBZ activated_VBN by_IN active_JJ
          Caspase_NNP 3_CD and_CC in_IN turn_NN cleaves_NNS lamin_NN ,_, resulting_VBG in_IN nuclear_JJ
          membrane_NN fragmentation_NN [_NN 55_CD ]_NN ._. FAF_NNP interacts_NNS with_IN the_DT
          cytoplasmic_JJ domain_NN of_IN the_DT Fas_NNP receptor_NN to_TO potentiate_NN
          Fas-mediated_NNP apoptosis_NNS [_NN 56_CD 57_CD ]_NN ._. Thus_RB ,_, the_DT up-regulated_JJ
          cell_NN cycle_NN inhibitors_NNS and_CC apoptotic_JJ proteins_NNS clearly_RB
          favor_VBP cell_NN cycle_NN arrest_NN and_CC death_NN ._.
          Among_IN signal_NN transduction_NN proteins_NNS with_IN altered_VBN
          expression_NN (_( Fig_NNP ._. 12_CD C_NNP )_) ,_, PNN_NNP analysis_NN shows_VBZ that_IN members_NNS of_IN
          all_DT three_CD growth_NN factor_NN pathways_NNS (_( Ras_NNP /_NN Raf_NNP ;_: JAK_NNP /_NN STAT_NNP ;_: JNK_NNP )_)
          have_VBP high_JJ relative_JJ importance_NN in_IN discriminating_VBG control_NN
          from_IN SN_NNP 50_CD -_: treated_VBN explants_NNS ._. Of_IN particular_JJ note_NN are_VBP c-_NN Raf_NNP ,_,
          ERK_NNP 2_CD ,_, and_CC JAK_NNP 1_CD ._. Raf_NNP plays_VBZ a_DT key_JJ role_NN in_IN the_DT Ras_NNP signaling_VBG
          pathway_NN (_( Fig_NNP ._. 1_LS )_) ._. That_DT ERK_NNP 2_CD is_VBZ of_IN very_RB high_JJ relative_JJ
          importance_NN is_VBZ consistent_JJ with_IN the_DT observation_NN that_IN the_DT
          MAPK_NNP /_NN ERK_NNP overrides_NNS apoptotic_JJ signaling_VBG from_IN Fas_NNP ,_, TNF_NNP and_CC
          TRAIL_NNP receptors_NNS [_NN 58_CD ]_NN ._. It_PRP appears_VBZ that_IN effectors_NNS apart_RB
          from_IN the_DT MAPK_NNP /_NN ERK_NNP pathway_NN may_MD also_RB mediate_VB the_DT
          anti-apoptotic_JJ function_NN of_IN c-_NN Raf_NNP [_NN 55_CD a_DT ]_NN ._. Further_RB ,_, both_DT the_DT
          SHP-_NNP 2_CD /_NN Ras_NNP and_CC JAK_NNP /_NN STAT_NNP 3_CD pathways_NNS are_VBP activated_VBN by_IN
          IL-_NNP 6_CD R_NN /_NN gp_NN 130_CD signaling_VBG (_( Fig_NNP ._. 1_LS )_) ._.
          Moreover_RB ,_, it_PRP is_VBZ especially_RB noteworthy_JJ that_IN the_DT nearly_RB
          2_CD -_: fold_VB 
          decline_NN of_IN glucocorticoid_NN receptor_NN
          (_( GR_NNP )_) (_( Table_NNP 2_LS )_) is_VBZ also_RB of_IN very_RB high_JJ relative_JJ importance_NN
          in_IN defining_VBG SMGs_NNP deprived_VBD of_IN NF-κB_NNP nuclear_JJ translocation_NN ._.
          As_IN noted_VBD above_IN ,_, CORT_NNP /_NN GR_NNP binding_VBG both_DT activates_NNS specific_JJ
          gene_NN expression_NN and_CC transrepresses_NNS NF-κB_NNP [_NN 47_CD ]_NN ._. To_TO
          repress_NNS NF-κB_NNP ,_, the_DT GR_NNP associates_NNS through_IN protein-protein_JJ
          interactions_NNS with_IN NF-κB_NNP bound_VBN at_IN κB_NN response_NN elements_NNS [_NN
          44_CD 45_CD 46_CD 47_CD ]_NN ._. The_DT precise_JJ relationship_NN between_IN
          decreased_VBD NF-κB-mediated_NNP transcription_NN and_CC a_DT decreased_VBD GR_NNP
          protein_NN expression_NN is_VBZ unclear_JJ ._.
          Nevertheless_RB ,_, CORT_NNP /_NN GR_NNP function_NN is_VBZ important_JJ to_TO
          embryonic_JJ SMG_NNP morphogenesis_NNS [_NN 60_CD ]_NN ._. Radioimmunoassays_NNP
          first_JJ detect_VB SMG_NNP CORT_NNP in_IN amounts_NNS >_NN 2_CD pg_NN /_NN gland_NN on_IN E_NNP 15_CD ;_:
          Western_JJ analysis_NN first_RB detects_NNS SMG_NNP GR_NNP on_IN E_NNP 14_CD (_( 0_CD ._. 14_CD
          fmol_NN /_NN gland_NN )_) ._. By_IN E_NNP 18_CD ,_, SMG_NNP CORT_NNP has_VBZ increased_VBN more_JJR than_IN
          50_CD -_: fold_VB ,_, and_CC SMG_NNP GR_NNP has_VBZ increased_VBN nearly_RB 11_CD -_: fold_VB ._. The_DT SMG_NNP
          GR_NNP is_VBZ functional_JJ ,_, as_IN defined_VBN by_IN its_PRP$ ability_NN to_TO bind_NN a_DT DNA_NNP
          response_NN element_NN (_( GRE_NNP )_) ._. Increasing_VBG CORT_NNP /_NN GR_NNP function_NN 
          in_IN vivo_NN is_VBZ associated_VBN with_IN a_DT
          significant_JJ decline_NN in_IN TGF-β_NNP expression_NN and_CC a_DT significant_JJ
          increase_NN in_IN cell_NN division_NN ._. SMG_NNP primordia_NN cultured_JJ under_IN
          serumless_JJ ,_, chemically_RB defined_VBN conditions_NNS ,_, and_CC deprived_VBD of_IN
          CORT_NNP ,_, exhibit_NN a_DT dramatic_JJ decline_NN of_IN SMG_NNP branching_VBG
          morphogenesis_NNS ._. It_PRP is_VBZ reasonable_JJ ,_, then_RB ,_, to_TO assume_VB that_IN the_DT
          high_JJ relative_JJ importance_NN of_IN diminished_VBN GR_NNP protein_NN
          expression_NN to_TO the_DT phenotype_NN of_IN SN_NNP 50_CD -_: treated_VBN SMGs_NNP is_VBZ
          directly_RB related_VBN to_TO the_DT significant_JJ (_( p_NN <_NN 0_CD ._. 001_CD )_)
          decline_NN in_IN cell_NN proliferation_NN and_CC branching_VBG (_( Fig_NNP ._. 3_LS A_DT ,_, B_NNP ;_:
          Fig_NNP ._. 4_LS A_DT )_) ._.
          The_DT iterated_JJ composite_JJ relative_JJ importance_NN of_IN all_DT 
          Connections_NNP Map_NNP proteins_NNS with_IN
          altered_VBN expression_NN as_IN a_DT consequence_NN of_IN NF-κB_NNP inhibition_NN
          was_VBD then_RB determined_VBN (_( Fig_NNP ._. 13_CD )_) ._. This_DT proteomic_JJ analysis_NN is_VBZ
          a_DT time-based_JJ "_'' snapshot_NN "_'' of_IN proteins_NNS assumed_VBD to_TO be_VB
          associated_VBN with_IN physiologic_JJ function_NN at_IN the_DT moment_NN of_IN SMG_NNP
          harvesting_NN ._. Viewing_NNP the_DT most_JJS defining_VBG proteins_NNS with_IN
          altered_VBN expression_NN ,_, it_PRP is_VBZ clearly_RB reflective_JJ of_IN increased_VBN
          apoptosis_NNS (_( increased_VBN Chk_NNP 1_CD ,_, Caspase_NNP 6_CD ,_, E_NNP 2_CD F_NN 1_LS )_) ,_, decreased_VBD
          cell_NN proliferation_NN and_CC branching_VBG (_( decreased_VBD GR_NNP )_) ,_, and_CC ,_,
          interestingly_RB ,_, increased_VBN expression_NN of_IN diverse_JJ signal_NN
          transduction_NN pathways_NNS (_( Ras_NNP /_NN Raf_NNP /_NN ERK_NNP ,_, JNK_NNP )_) to_TO compensate_VB
          for_IN the_DT proapoptotic_JJ signal_NN ._.
        
        
          Analysis_NNP of_IN activated_VBN pathway_NN components_NNS
          We_PRP then_RB focused_VBD our_PRP$ attention_NN on_IN two_CD particularly_RB
          important_JJ pathways_NNS relative_JJ to_TO cell_NN proliferation_NN and_CC
          apoptosis_NNS ,_, ERK_NNP 1_CD /_NN 2_CD and_CC Caspase_NNP 3_CD ._. Downstream_NNP of_IN 
          activated_VBN ERK_NNP 1_CD /_NN 2_CD is_VBZ an_DT
          upregulation_NN of_IN cell_NN proliferation_NN proteins_NNS and_CC
          potentially_RB enhanced_JJ cell_NN division_NN ,_, as_RB well_RB as_IN a_DT
          protective_JJ effect_NN over_IN apoptotic_JJ signaling_VBG via_IN suppressed_VBN
          activation_NN of_IN caspase_NN effectors_NNS ._. Downstream_NNP of_IN 
          activated_VBN Caspase_NNP 3_CD are_VBP the_DT
          sequellae_NN of_IN apoptosis_NNS ,_, including_VBG PARP_NNP cleavage_NN and_CC
          inhibition_NN of_IN DNA_NNP repair_NN ,_, DNA_NNP fragmentation_NN ,_, and_CC nuclear_JJ
          membrane_NN fragmentation_NN ._. The_DT increase_NN or_CC decrease_VB in_IN
          expression_NN of_IN the_DT components_NNS of_IN any_DT signaling_VBG pathway_NN is_VBZ
          not_RB necessarily_RB probative_JJ of_IN pathway_NN activity_NN ._. Rather_RB ,_, it_PRP
          is_VBZ the_DT change_NN in_IN the_DT level_NN of_IN activated_VBN protein_NN that_WDT is_VBZ 
          physiologically_RB important_JJ ._. Thus_RB ,_, we_PRP
          determined_VBD if_IN SN_NNP 50_CD treatment_NN was_VBD associated_VBN with_IN
          activation_NN of_IN the_DT ERK_NNP 1_CD /_NN 2_CD and_CC Caspase_NNP 3_CD pathways_NNS ,_, using_VBG
          E_NNP 15_CD +_NN 2_CD control_NN and_CC SN_NNP 50_CD -_: treated_VBN explants_NNS ,_, 1_CD -_: D_NNP Western_JJ
          blot_NN analysis_NN ,_, and_CC antibodies_NNS specific_JJ to_TO 
          activated_VBN (_( phosphorylated_JJ /_NN cleaved_JJ )_)
          proteins_NNS ._. Specifically_RB ,_, we_PRP evaluated_VBD the_DT levels_NNS of_IN
          activated_VBN c-_NN Raf_NNP ,_, ERK_NNP 1_CD /_NN 2_CD ,_, Caspase_NNP 3_CD ,_, and_CC PARP_NNP using_VBG
          antibodies_NNS which_WDT identify_VBP only_RB the_DT phosphorylated_JJ or_CC
          cleaved_JJ proteins_NNS and_CC do_VBP not_RB cross_VB react_VB with_IN the_DT inactive_JJ
          protein_NN ._. We_PRP found_VBD a_DT significant_JJ increase_NN (_( p_NN <_NN 0_CD ._. 05_CD )_) in_IN
          
          activated_VBN ERK_NNP 1_CD /_NN 2_CD ,_, Caspase_NNP 3_CD ,_, and_CC
          PARP_NNP in_IN SN_NNP 50_CD -_: treated_VBN explants_NNS (_( Fig_NNP ._. 14_CD )_) ;_: no_DT change_NN was_VBD
          seen_VBN in_IN 
          activated_VBN c-_NN Raf_NNP levels_NNS between_IN
          control_NN and_CC SN_NNP 50_CD -_: treated_VBN explants_NNS ._. The_DT greater_JJR than_IN
          2_CD -_: fold_VB increase_NN in_IN Caspase_NNP 3_CD activation_NN is_VBZ associated_VBN
          with_IN a_DT 1_CD ._. 8_CD -_: fold_VB increase_NN in_IN PARP_NNP cleavage_NN (_( Fig_NNP ._. 14_CD )_) and_CC a_DT
          10_CD -_: fold_VB increase_NN in_IN apoptosis_NNS (_( Fig_NNP ._. 4_LS B_NNP )_) ._. Since_IN Caspase_NNP 3_CD
          is_VBZ nodal_NN to_TO E_NNP 2_CD F_NN 1_CD (_( via_IN p_NN 53_CD )_) ,_, FAF_NNP (_( via_IN Fas_NNP /_NN Caspase_NNP 8_CD )_) ,_, and_CC
          Caspase_NNP 6_CD [_NN 33_CD 36_CD 37_CD 39_CD ]_NN ,_, our_PRP$ observation_NN of_IN increased_VBN 
          activated_VBN Caspase_NNP 3_CD is_VBZ consistent_JJ
          with_IN the_DT increased_VBN levels_NNS of_IN E_NNP 2_CD F_NN 1_CD ,_, FAF_NNP ,_, and_CC Caspase_NNP 6_CD
          proteins_NNS (_( Table_NNP 2_LS )_) ._. Regarding_VBG the_DT ERK_NNP 1_CD /_NN 2_CD pathway_NN ,_, we_PRP
          found_VBD a_DT greater_JJR than_IN 2_CD -_: fold_VB increase_NN of_IN activated_VBN ERK_NNP 2_CD in_IN
          SN_NNP 50_CD -_: treated_VBN glands_NNS (_( Fig_NNP ._. 13_CD )_) associated_VBN with_IN a_DT 1_CD ._. 5_CD -_: fold_VB
          increase_NN in_IN total_JJ ERK_NNP 2_CD protein_NN (_( Table_NNP 2_LS )_) ._. This_DT increased_VBN
          activity_NN of_IN proapoptotic_JJ (_( caspase_NN 3_CD /_NN PARP_NNP )_) and_CC compensatory_JJ
          antiapoptotic_JJ (_( ERK_NNP 1_CD /_NN 2_LS )_) pathways_NNS is_VBZ consistent_JJ with_IN the_DT
          dramatic_JJ cell_NN death_NN seen_VBN in_IN SN_NNP 50_CD -_: treated_VBN SMGs_NNP ._.
          Paradoxically_NNP ,_, increased_VBD ERK_NNP 1_CD activation_NN is_VBZ seen_VBN despite_IN
          a_DT 1_CD ._. 6_CD -_: fold_VB decrease_VB in_IN total_JJ ERK_NNP 1_CD protein_NN (_( Table_NNP 2_LS )_) and_CC
          increased_VBN ERK_NNP 1_CD /_NN 2_CD activation_NN is_VBZ associated_VBN with_IN virtually_RB
          no_DT change_NN in_IN the_DT antecedent_NN activation_NN of_IN c-_NN Raf_NNP ._. The_DT
          latter_NN is_VBZ consistent_JJ with_IN the_DT demonstration_NN that_DT c-_NN Raf_NNP
          function_NN is_VBZ not_RB mediated_JJ by_IN the_DT MAPK_NNP /_NN ERK_NNP cascade_NN [_NN 59_CD ]_NN ._.
          Moreover_RB ,_, although_IN we_PRP find_VBP an_DT increase_NN in_IN total_JJ Raf_NNP
          protein_NN (_( Table_NNP 2_LS )_) ,_, no_DT increase_NN in_IN activated_VBN c-_NN Raf_NNP is_VBZ
          found_VBN ;_: we_PRP also_RB see_VBP a_DT 2_CD -_: fold_VB increase_NN in_IN activated_VBN Caspase_NNP
          3_CD but_CC no_DT change_NN in_IN total_JJ Caspase_NNP 3_CD protein_NN ._. These_DT results_NNS
          clearly_RB illustrate_VBP that_IN changes_NNS in_IN 
          total_JJ protein_NN level_NN are_VBP not_RB always_RB
          indicative_JJ of_IN altered_VBN protein_NN 
          activity_NN ._. 
          Finally_RB ,_, it_PRP should_MD be_VB noted_VBN that_IN a_DT recent_JJ study_NN using_VBG
          cell_NN lines_NNS raised_VBD the_DT possibility_NN that_IN SN_NNP 50_CD 's_POS action_NN is_VBZ
          not_RB specific_JJ to_TO NF-κB_NNP [_NN 61_CD 62_CD ]_NN ._. SN_NNP 50_CD is_VBZ composed_VBN of_IN the_DT
          NLS_NNP for_IN NF-κB_NNP p_NN 50_CD and_CC was_VBD believed_VBN to_TO specifically_RB block_VB
          NF-κB_NNP p_NN 50_CD /_NN p_NN 65_CD nuclear_JJ translocation_NN by_IN binding_VBG the_DT NLS_NNP
          receptor_NN complex_JJ and_CC preventing_VBG transport_NN through_IN the_DT
          nuclear_JJ pore_NN [_NN 33_CD 34_CD 35_CD ]_NN ._. However_RB ,_, Torgerson_NNP and_CC
          coworkers_NNS [_NN 61_CD ]_NN have_VBP shown_VBN that_IN SN_NNP 50_CD treatment_NN inhibited_VBD
          nuclear_JJ transport_NN of_IN transcription_NN factors_NNS NFAT_NNP ,_, AP-_NNP 1_CD ,_,
          STAT_NNP 1_CD ,_, and_CC NF-κB_NNP at_IN a_DT high_JJ dose_NN of_IN 210_CD μg_NN /_NN ml_NN in_IN Junkrat_NNP
          cells_NNS ._. However_RB ,_, others_NNS have_VBP shown_VBN that_IN lower_JJR doses_NNS ≤_NN 100_CD
          μg_NN /_NN ml_NN of_IN SN_NNP 50_CD specifically_RB inhibited_VBD NF-κB_NNP nuclear_JJ
          translocation_NN in_IN human_JJ peripheral_JJ blood_NN lymphocytes_NNS and_CC
          murine_NN T_NN cells_NNS [_NN 33_CD 63_CD ]_NN ._. These_DT reported_VBD differences_NNS are_VBP
          likely_JJ due_NN to_TO dose-dependent_JJ or_CC cell-specific_JJ differences_NNS
          in_IN the_DT effect_NN of_IN SN_NNP 50_CD [_NN 64_CD ]_NN ._. Given_VBN that_IN :_: (_( 1_LS )_) embryonic_JJ
          SMGs_NNP were_VBD cultured_JJ in_IN the_DT presence_NN of_IN 100_CD μg_NN /_NN ml_NN SN_NNP 50_CD ,_, (_( 2_LS )_)
          immunodetectable_JJ NF-κB_NNP was_VBD absent_JJ from_IN SMG_NNP epithelia_NN
          nuclei_NN in_IN TNF_NNP +_NN SN_NNP 50_CD -_: treated_VBN explants_NNS ,_, and_CC (_( 3_LS )_) one_CD cannot_NN
          extrapolate_NN observations_NNS in_IN Jurkat_NNP cells_NNS to_TO those_DT in_IN
          primary_JJ cells_NNS [_NN 64_CD ]_NN or_CC organ_NN cultures_NNS ,_, it_PRP is_VBZ most_RBS
          probable_JJ that_IN our_PRP$ observed_JJ interruption_NN of_IN SMG_NNP
          development_NN is_VBZ proximately_RB due_JJ exclusively_RB to_TO the_DT
          inhibition_NN of_IN NF-κB_NNP nuclear_JJ translocation_NN ._. Indeed_RB ,_, for_IN
          low_JJ doses_NNS of_IN SN_NNP 50_CD ,_, there_EX is_VBZ no_DT evidence_NN in_IN the_DT literature_NN
          to_TO the_DT contrary_NN ._. Nonetheless_RB ,_, we_PRP do_VBP recognize_VB that_DT
          absence_NN of_IN evidence_NN is_VBZ not_RB necessarily_RB evidence_NN of_IN
          absence_NN ._.
        
      
      
        Conclusions_NNP
        Our_PRP$ results_NNS indicate_VBP that_IN NF-κB-mediated_NNP transcription_NN
        is_VBZ directly_RB or_CC indirectly_RB critical_JJ to_TO embryonic_JJ SMG_NNP
        developmental_NN homeostasis_NNS ._. We_PRP demonstrate_VBP the_DT interplay_NN
        between_IN gene_NN expression_NN ,_, protein_NN expression_NN ,_, protein_NN
        activity_NN ,_, and_CC morphology_NN in_IN response_NN to_TO NF-κB_NNP inhibition_NN ._.
        Gene_NNP /_NN protein_NN differences_NNS between_IN control_NN and_CC
        NF-κB-inhibited_NNP phenotypes_NNS are_VBP not_RB linearly_RB causal_NN of_IN SMG_NNP
        dysplasia_NN ._. In_IN fact_NN ,_, these_DT differences_NNS are_VBP discovered_VBN
        correlations_NNS between_IN network_NN components_NNS and_CC an_DT emerging_VBG SMG_NNP
        phenotype_NN ,_, a_DT glimpse_NN of_IN nonlinear_NN organogenesis_NNS [_NN 65_CD ]_NN
        ._.
        Considering_VBG the_DT outcome_NN of_IN this_DT study_NN relative_JJ to_TO the_DT 
        Connections_NNP Map_NNP (_( Fig_NNP ._. 1_LS )_) ,_, it_PRP is_VBZ
        apparent_JJ that_IN NF-κB_NNP nuclear_JJ translocation_NN is_VBZ functionally_RB
        integral_JJ to_TO a_DT genetic_JJ network_NN with_IN broadly_RB related_VBN ,_, rather_RB
        than_IN independent_JJ ,_, components_NNS ._. It_PRP may_MD be_VB said_VBN to_TO represent_VB
        the_DT collective_JJ dynamics_NNS of_IN a_DT "_'' small-world_JJ "_'' network_NN such_JJ
        that_IN the_DT average_JJ number_NN of_IN factors_NNS in_IN the_DT shortest_JJS chain_NN
        connecting_VBG any_DT two_CD factors_NNS is_VBZ small_JJ [_NN 66_CD ]_NN ._. Such_JJ dynamical_JJ
        systems_NNS with_IN small-world_JJ coupling_NN display_NN enhanced_VBD
        signal-propagation_JJ speed_NN and_CC synchronizability_NN ._. Thus_RB ,_, if_IN
        one_CD focuses_VBZ on_IN the_DT superimposition_NN of_IN the_DT various_JJ layers_NNS of_IN
        information_NN ,_, namely_RB morphology_NN ,_, gene_NN expression_NN ,_, protein_NN
        expression_NN ,_, and_CC protein_NN activity_NN (_( Figs_NNP ._. 3_LS ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ,_,
        9_CD ,_, 10_CD ,_, 11_CD ,_, 12_CD ,_, 13_CD ,_, 14_CD )_) ,_, one_PRP can_MD visualize_VB a_DT coordinated_VBN ,_,
        multidimensional_NN response_NN to_TO inhibited_VBD NF-κB_NNP nuclear_JJ
        translocation_NN ._. This_DT visualization_NN ,_, however_RB ,_, is_VBZ necessarily_RB
        impressionistic_JJ even_RB though_IN our_PRP$ assays_NNS have_VBP some_DT precision_NN ._.
        This_DT is_VBZ so_RB because_IN we_PRP cannot_NN extrapolate_NN from_IN transcriptome_NN
        to_TO proteome_NN to_TO activated_VBN proteins_NNS with_IN any_DT accuracy_NN (_( in_IN the_DT
        absence_NN of_IN actual_JJ steady-state_JJ measures_NNS )_) ,_, 
        and_CC because_IN in_IN these_DT experiments_NNS time_NN
        is_VBZ necessarily_RB cross-sectional_JJ ,_, not_RB longitudinal_NN ._.
        Nevertheless_RB ,_, relative_JJ to_TO understanding_VBG a_DT complex_JJ genetic_JJ
        network_NN and_CC organogenesis_NNS ,_, our_PRP$ results_NNS demonstrate_VBP the_DT
        importance_NN of_IN contemporaneously_RB evaluating_VBG the_DT gene_NN ,_,
        protein_NN ,_, 
        and_CC activated_VBN protein_NN expression_NN of_IN
        multiple_JJ components_NNS from_IN multiple_JJ pathways_NNS within_IN broad_JJ
        functional_JJ categories_NNS ._. Understanding_NNP the_DT signal_NN dynamics_NNS of_IN
        these_DT pathways_NNS will_MD require_VB expanded_VBN models_NNS that_WDT encompass_VB
        more_JJR aspects_NNS of_IN regulation_NN [_NN e_SYM ._. g_SYM ._. [_NN 67_CD ]_NN ]_NN ._. Still_RB ,_, we_PRP will_MD
        always_RB be_VB limited_VBN by_IN the_DT fact_NN that_IN phenotypes_NNS are_VBP complex_JJ ,_,
        emergent_NN phenomena_NNS [_NN 16_CD ]_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Tissue_NNP collection_NN
          Female_NNP B_NNP 10_CD A_DT /_NN SnSg_NNP mice_NNS ,_, obtained_VBN from_IN Jackson_NNP
          Laboratories_NNPS (_( Bar_NNP Harbor_NNP ,_, ME_NNP )_) ,_, were_VBD maintained_VBN and_CC mated_VBN
          as_RB previously_RB described_VBD [_NN 60_CD ]_NN ;_: plug_NN day_NN =_SYM day_NN 0_CD of_IN
          gestation_NN ._. Pregnant_NNP females_NNS were_VBD anesthetized_JJ on_IN days_NNS
          15_CD -_: 19_CD of_IN gestation_NN (_( E_NNP 15_CD -_: 18_CD )_) with_IN methoxyflurane_NN
          (_( metafane_NN )_) and_CC euthanized_JJ by_IN cervical_JJ dislocation_NN ._.
          Embryos_NNP were_VBD dissected_VBN in_IN cold_JJ phosphate_NN buffered_JJ saline_NN
          (_( PBS_NNP )_) and_CC staged_VBD according_VBG to_TO Theiler_NNP [_NN 68_CD ]_NN ._. SMGs_NNP were_VBD
          dissected_VBN and_CC cultured_JJ ,_, processed_VBN for_IN histology_NN ,_, or_CC
          stored_VBD at_IN -_: 70_CD °_NN C_NNP ._. For_IN cDNA_NN expression_NN and_CC proteomic_JJ
          studies_NNS ,_, E_NNP 15_CD +_NN 2_CD explants_NNS were_VBD collected_VBN ,_, pooled_VBN ,_, and_CC
          stored_VBD at_IN -_: 70_CD °_NN C_NNP ._.
        
        
          Culture_NNP system_NN
          E_NNP 15_CD SMG_NNP (_( mostly_RB 
          Canalicular_NNP Stage_NNP )_) primordia_NN were_VBD
          cultured_JJ using_VBG a_DT modified_VBN Trowell_NNP method_NN as_RB previously_RB
          described_VBD [_NN 13_CD ]_NN ._. The_DT medium_NN consisted_VBD of_IN BGJb_NNP (_( Life_NNP
          Technologies_NNPS ,_, Rockville_NNP ,_, MD_NNP )_) supplemented_JJ with_IN 0_CD ._. 5_CD mg_NN
          ascorbic_JJ acid_NN /_NN ml_NN and_CC 50_CD units_NNS penicillin_NN /_NN streptomycin_NN
          (_( Life_NNP Technologies_NNPS )_) ,_, pH_NN 7_CD ._. 2_CD ,_, and_CC replicate_VB cultures_NNS were_VBD
          changed_VBN every_DT other_JJ day_NN ._. Cultures_NNP were_VBD supplemented_JJ on_IN
          day_NN 0_CD and_CC maintained_VBN for_IN the_DT duration_NN of_IN the_DT experiments_NNS ._.
          In_IN each_DT of_IN the_DT enumerated_JJ studies_NNS ,_, a_DT minimum_NN of_IN 12_CD
          explants_NNS were_VBD cultured_JJ for_IN 2_CD or_CC 4_CD days_NNS in_IN the_DT cell_NN
          permeable_JJ peptide_NN SN_NNP 50_CD (_( Biomol_NNP Research_NNP ,_, Plymouth_NNP
          Meeting_VBG ,_, PA_NNP )_) which_WDT inhibits_NNS NF-κB_NNP translocation_NN into_IN the_DT
          nucleus_NN [_NN 24_CD 33_CD 34_CD 35_CD ]_NN ._. The_DT concentration_NN used_VBN (_( 100_CD
          μg_NN /_NN ml_NN )_) was_VBD double_JJ that_WDT shown_VBN to_TO inhibit_VB NF-κB_NNP
          translocation_NN in_IN mouse_NN endothelial_NN LE-II_NNP cells_NNS ;_: 100_CD μg_NN /_NN ml_NN
          mutant_JJ SN_NNP 50_CD (_( mSN_NN 50_CD )_) peptide_NN was_VBD used_VBN as_IN a_DT 
          positive_JJ control_NN and_CC control_NN BGJb_NNP
          medium_NN as_IN a_DT 
          negative_JJ control_NN ._. We_PRP evaluated_VBD
          their_PRP$ microanatomy_NN by_IN routine_JJ hematoxylin_NN and_CC eosin_NN
          histology_NN ._. We_PRP report_VBP a_DT marked_VBN difference_NN between_IN
          SN_NNP 50_CD -_: treated_VBN and_CC control_NN explants_NNS or_CC SN_NNP 50_CD -_: and_CC mSN_NN 50_CD
          peptide-treated_JJ explants_NNS ._. No_DT differences_NNS were_VBD observed_VBN
          between_IN control_NN and_CC mSN_NN 50_CD -_: treated_VBN explants_NNS ._. Since_IN these_DT
          initial_JJ studies_NNS demonstrated_VBD no_DT difference_NN between_IN
          explants_NNS cultured_JJ in_IN control_NN media_NNS alone_RB and_CC in_IN mutant_JJ
          peptide_NN ,_, control_NN media_NNS was_VBD used_VBN as_IN the_DT control_NN in_IN all_DT
          subsequent_JJ experiments_NNS ._. Ten_CD independent_JJ experiments_NNS of_IN
          E_NNP 15_CD primordia_NN were_VBD cultured_JJ for_IN 2_CD days_NNS (_( E_NNP 15_CD +_NN 2_LS )_) in_IN CONT_NNP
          (_( control_NN )_) or_CC SN_NNP 50_CD -_: supplemented_JJ media_NNS ,_, each_DT group_NN
          consisting_VBG of_IN a_DT minimum_NN of_IN 8_CD explants_NNS per_IN group_NN ._. E_NNP 15_CD +_NN 2_CD
          explants_NNS were_VBD collected_VBN and_CC processed_VBN as_IN described_VBN
          below_IN ._.
          To_TO further_VB demonstrate_VB that_IN SN_NNP 50_CD treatment_NN inhibited_VBD
          NB-κB_NNP activation_NN ,_, we_PRP evaluated_VBD if_IN TNF_NNP supplementation_NN
          would_MD induce_VB NF-κB_NNP translocation_NN and_CC SMG_NNP morphogenesis_NNS ._.
          E_NNP 15_CD SMGs_NNP were_VBD cultured_JJ for_IN 4_CD days_NNS or_CC longer_JJR in_IN 10_CD U_NNP /_NN ml_NN
          recombinant_JJ mouse_NN TNF_NNP (_( rTNF_NN ,_, R_NN &_CC D_NNP ,_, Minneapolis_NNP ,_, MN_NNP )_) ,_,
          100_CD μg_NN /_NN ml_NN SN_NNP 50_CD +_NN 10_CD U_NNP /_NN ml_NN rTNF_NN ,_, or_CC 100_CD μg_NN /_NN ml_NN mSN_NN 50_CD +_NN 10_CD
          U_NNP /_NN ml_NN rTNF_NN ,_, 6_CD -_: 10_CD explants_NNS per_IN treatment_NN group_NN ._. This_DT rTNF_NN
          concentration_NN was_VBD previously_RB shown_VBN in_IN our_PRP$ laboratory_NN to_TO
          induce_VB embryonic_JJ SMG_NNP morphogenesis_NNS and_CC cell_NN proliferation_NN
          [_NN 13_CD ]_NN ._. Explants_NNP were_VBD collected_VBN and_CC evaluated_VBN by_IN
          histological_JJ and_CC immunochemical_JJ analyses_NNS as_IN described_VBN
          below_IN ._.
        
        
          Histology_NNP and_CC immunolocalization_NN
          SMGs_NNP were_VBD fixed_VBN in_IN Carnoy_NNP 's_POS fixative_JJ ,_, processed_VBN ,_,
          embedded_VBN in_IN low-melting_JJ point_NN paraplast_NN ,_, and_CC stored_VBD for_IN
          brief_JJ periods_NNS at_IN 4_CD °_NN C_NNP as_RB previously_RB described_VBD [_NN 13_CD ]_NN ._.
          Cultured_NNP explant_NN morphogenesis_NNS was_VBD analyzed_VBN by_IN dissecting_VBG
          microscopy_NN and_CC by_IN light_JJ microscopy_NN of_IN serial_NN sections_NNS
          stained_JJ with_IN hematoxylin_NN and_CC eosin_NN ._. A_DT minimum_NN of_IN 5_CD
          explants_NNS per_IN group_NN was_VBD evaluated_VBN for_IN all_DT experimental_JJ
          groups_NNS ._. For_IN immunochemistry_NN ,_, the_DT tissues_NNS were_VBD sectioned_JJ
          at_IN 7_CD μm_NN ,_, placed_VBN on_IN cleaned_VBN ,_, gelatin-coated_JJ slides_NNS at_IN 37_CD °_NN C_NNP
          for_IN 3_CD hr_NN ,_, and_CC immediately_RB immunostained_JJ as_IN previously_RB
          described_VBD [_NN 9_CD 13_CD ]_NN ._. The_DT sections_NNS were_VBD incubated_JJ in_IN
          polyclonal_NN goat_NN anti-_NN NF-κB_NNP p_NN 65_CD /_NN RelA_NNP antibody_NN (_( C-_NNP 20_CD )_) (_( Santa_NNP
          Cruz_NNP Biotechnology_NNP ,_, Santa_NNP Cruz_NNP ,_, CA_NNP )_) ;_: this_DT antibody_NN has_VBZ
          been_VBN shown_VBN to_TO cross-react_JJ with_IN mouse_NN p_NN 65_CD ;_: it_PRP is_VBZ not_RB
          cross-reactive_JJ with_IN RelB_NNP p_NN 68_CD or_CC c-_NN Rel_NNP p_NN 75_CD ._. We_PRP confirmed_VBD
          the_DT spatial_NN distribution_NN of_IN NF-κB_NNP using_VBG a_DT polyclonal_NN goat_NN
          anti-_NN NF-κB_NNP p_NN 50_CD antibody_NN (_( C-_NNP 19_CD )_) (_( Santa_NNP Cruz_NNP
          Biotechnology_NNP )_) ;_: this_DT antibody_NN has_VBZ been_VBN shown_VBN to_TO react_VB
          with_IN mouse_NN p_NN 50_CD or_CC p_NN 105_CD ;_: it_PRP is_VBZ not_RB cross-reactive_JJ with_IN
          NF-κB_NNP p_NN 52_CD ,_, p_NN 65_CD /_NN RelA_NNP or_CC p_NN 100_CD ._. Controls_NNP consisted_VBD of_IN
          sections_NNS incubated_JJ with_IN preimmune_NN serum_NN or_CC in_IN the_DT absence_NN
          of_IN primary_JJ antibody_NN ;_: controls_NNS were_VBD routinely_RB negative_JJ ._.
          The_DT spatial_NN distribution_NN of_IN NF-κB_NNP p_NN 65_CD was_VBD identical_JJ to_TO
          that_DT of_IN NF-κB_NNP p_NN 50_CD ._. Therefore_RB ,_, we_PRP only_RB show_VBP the_DT results_NNS of_IN
          the_DT anti-_NN NF-κB_NNP p_NN 65_CD antibody_NN experiments_NNS ._.
        
        
          Quantitation_NNP of_IN activated_VBN p_NN 53_CD
          To_TO quantitate_NN differences_NNS in_IN 
          activated_VBN (_( phosphorylated_JJ )_) p_NN 53_CD
          protein_NN ,_, 3_CD SN_NNP 50_CD and_CC control_NN E_NNP 15_CD +_NN 2_CD explants_NNS were_VBD
          sectioned_JJ ,_, preincubated_JJ with_IN unlabeled_JJ goat-anti_JJ mouse_NN
          IgG_NNP as_RB previously_RB described_VBD [_NN 9_CD ]_NN and_CC sequentially_RB
          incubated_JJ with_IN a_DT monoclonal_NN anti-phosphorylated_JJ p_NN 53_CD
          (_( Ser_NNP 15_CD )_) antibody_NN (_( Cell_NNP Signaling_NNP Technology_NNP ,_, Beverly_NNP ,_,
          MA_NNP )_) ,_, biotin-labeled_JJ goat_NN anti-mouse_JJ IgG_NNP ,_, and_CC HRP-labeled_NNP
          SA_NNP (_( Zymed_NNP Laboratories_NNPS ,_, South_NNP San_NNP Francisco_NNP ,_, CA_NNP )_) ,_, and_CC
          counterstained_JJ with_IN hematoxylin_NN ._. Controls_NNP consisted_VBD of_IN
          preimmune_NN serum_NN or_CC PBS_NNP alone_RB ._. In_IN this_DT set_JJ of_IN experiments_NNS ,_,
          the_DT cytoplasm_NN appears_VBZ blue_JJ and_CC 
          activated_VBN p_NN 53_CD -_: positive_JJ cells_NNS appear_VBP
          dark_JJ brown_JJ ._. Three_CD sections_NNS per_IN group_NN were_VBD selected_VBN and_CC 3_CD
          areas_NNS per_IN section_NN was_VBD photographed_VBN at_IN 200_CD ×_NN ._. p_NN 53_CD -_: positive_JJ
          epithelial_NN cells_NNS /_NN total_JJ epithelial_NN cells_NNS were_VBD determined_VBN
          per_IN area_NN and_CC the_DT mean_NN ratios_NNS per_IN section_NN and_CC per_IN group_NN
          were_VBD determined_VBN ._. Statistical_NNP comparisons_NNS were_VBD made_VBN
          between_IN CONT_NNP and_CC SN_NNP 50_CD -_: treated_VBN E_NNP 15_CD +_NN 2_CD explants_NNS as_IN
          described_VBN below_IN ._.
        
        
          Cell_NNP proliferation_NN assay_NN
          E_NNP 15_CD +_NN 2_CD CONT_NNP or_CC SN_NNP 50_CD -_: treated_VBN explants_NNS were_VBD sectioned_JJ ,_,
          incubated_JJ with_IN anti-_NN PCNA_NNP using_VBG the_DT Zymed_NNP mouse_NN PCNA_NNP kit_NN
          (_( South_NNP San_NNP Francisco_NNP ,_, CA_NNP )_) ,_, and_CC counterstained_JJ with_IN
          hematoxylin_NN as_RB previously_RB described_VBD [_NN 13_CD ]_NN ._. In_IN this_DT set_JJ
          of_IN experiments_NNS ,_, the_DT cytoplasm_NN appears_VBZ blue_JJ and_CC
          PCNA-positive_NNP cells_NNS appear_VBP dark_JJ brown_JJ ._. Quantitation_NNP of_IN
          cell_NN proliferation_NN was_VBD conducted_VBN as_IN described_VBN above_IN for_IN
          p_NN 53_CD ._. Cell_NNP proliferation_NN is_VBZ presented_VBN as_IN the_DT ratio_NN of_IN
          PCNA-positive_NNP epithelial_NN cells_NNS /_NN total_JJ epithelial_NN cells_NNS ._.
          Mean_VB ratios_NNS per_IN section_NN and_CC mean_VB ratios_NNS per_IN group_NN were_VBD
          determined_VBN ._. Statistical_NNP comparisons_NNS were_VBD made_VBN between_IN
          CONT_NNP and_CC SN_NNP 50_CD -_: treated_VBN E_NNP 15_CD +_NN 2_CD explants_NNS as_IN described_VBN
          below_IN ._.
        
        
          Apoptosis_NNP assay_NN
          Apoptotic_NNP cells_NNS were_VBD detected_VBN using_VBG a_DT monoclonal_NN
          antibody_NN to_TO single-stranded_JJ DNA_NNP (_( ssDNA_NN )_) (_( Mab_NNP F_NNP 7_CD -_: 26_CD )_)
          according_VBG to_TO the_DT method_NN of_IN Apostain_NNP ,_, Inc_NNP ._. (_( Miami_NNP ,_, FL_NNP )_) [_NN
          13_CD ]_NN ._. Selective_NNP binding_JJ of_IN anti-ss_JJ DNA_NNP monoclonal_NN
          antibody_NN F_NN 7_CD -_: 26_CD to_TO 
          apoptotic_JJ nuclei_NN reflects_VBZ decreased_VBN
          stability_NN of_IN DNA_NNP to_TO thermal_JJ denaturation_NN ._. Four_CD positive_JJ
          and_CC negative_JJ controls_NNS were_VBD conducted_VBN ._. 
          Negative_JJ controls_NNS :_: (_( 1_LS )_) Tissue_NNP
          sections_NNS were_VBD heated_JJ and_CC treated_VBN with_IN S_NNP 1_CD nuclease_NN
          (_( Sigma_NNP )_) ;_: S_NNP 1_CD nuclease_NN eliminates_VBZ staining_VBG of_IN apoptotic_JJ
          cells_NNS ,_, thus_RB demonstrating_VBG that_IN Mab_NNP F_NNP 7_CD -_: 26_CD binds_NNS
          specifically_RB to_TO ssDNA_NN ._. (_( 2_LS )_) Sections_NNP were_VBD pretreated_JJ in_IN
          PBS_NNP containing_VBG lysine-rich_JJ histone_NN (_( Sigma_NNP )_) prior_RB to_TO
          heating_NN and_CC immunostaining_VBG ;_: reconstitution_NN with_IN histone_NN
          restores_NNS DNA_NNP stability_NN in_IN apoptotic_JJ nuclei_NN ,_, thus_RB
          preventing_VBG DNA_NNP denaturation_NN and_CC eliminating_VBG Mab_NNP staining_VBG
          of_IN apoptotic_JJ cells_NNS ._. 
          Positive_JJ controls_NNS :_: (_( 1_LS )_) Sections_NNP
          were_VBD heated_JJ in_IN water_NN and_CC treated_VBN with_IN Mab_NNP ;_: bright_JJ
          staining_VBG of_IN all_DT non-apoptotic_JJ nuclei_NN with_IN low_JJ apoptotic_JJ
          indexes_NNS demonstrates_VBZ that_IN the_DT procedure_NN is_VBZ adequate_JJ to_TO
          detect_VB ssDNA_NN ._. (_( 2_LS )_) Sections_NNP were_VBD pretreated_JJ with_IN
          proteinase_NN K_NNP before_IN heating_VBG ;_: intensive_JJ staining_VBG of_IN
          non-apoptotic_JJ nuclei_NN demonstrates_VBZ that_IN the_DT procedure_NN
          detects_NNS decreased_VBD DNA_NNP stability_NN induced_VBN by_IN the_DT digestion_NN
          of_IN nuclear_JJ proteins_NNS ._. Mab_NNP F_NNP 7_CD -_: 26_CD was_VBD purchased_VBN from_IN
          Apostain_NNP ,_, Inc_NNP ._.
          Apoptotic_NNP nuclei_NN appear_VBP as_IN dark_JJ brown_JJ ._. Since_IN the_DT
          sections_NNS were_VBD not_RB counterstained_JJ with_IN hematoxylin_NN in_IN this_DT
          set_JJ of_IN experiments_NNS ,_, epithelial_NN cell_NN cytoplasm_NN appears_VBZ as_IN
          light_JJ brown_JJ ._. Only_RB apoptotic_JJ (_( variously_RB intense_JJ dark_JJ
          brown_JJ )_) nuclei_NN were_VBD counted_VBN in_IN control_NN and_CC SN_NNP 50_CD -_: treated_VBN
          sections_NNS ._. Apoptosis_NNP was_VBD evaluated_VBN in_IN a_DT minimum_NN of_IN 4_CD
          explants_NNS per_IN experimental_JJ group_NN ._. Quantitation_NNP of_IN
          apoptotic_JJ nuclei_NN was_VBD conducted_VBN as_IN described_VBN above_IN for_IN
          p_NN 53_CD ._. Apoptosis_NNP is_VBZ presented_VBN as_IN the_DT ratio_NN of_IN
          apoptotic-positive_JJ epithelial_NN cell_NN nuclei_NN /_NN total_JJ
          epithelial_NN cell_NN nuclei_NN ._. Mean_VB ratios_NNS per_IN section_NN and_CC mean_VB
          ratios_NNS per_IN group_NN were_VBD determined_VBN ._. Statistical_NNP comparisons_NNS
          were_VBD made_VBN between_IN CONT_NNP and_CC SN_NNP 50_CD -_: treated_VBN E_NNP 15_CD +_NN 2_CD explants_NNS
          as_IN described_VBN below_IN ._.
        
        
          cDNA_NN expression_NN arrays_NNS
          For_IN cDNA_NN Expression_NNP Array_NNP analysis_NN ,_, E_NNP 15_CD SMG_NNP primordia_NN
          were_VBD cultured_JJ in_IN the_DT presence_NN or_CC absence_NN of_IN SN_NNP 50_CD peptide_NN
          for_IN 2_CD days_NNS (_( E_NNP 15_CD +_NN 2_LS )_) ,_, collected_VBN in_IN cold_JJ PBS_NNP containing_VBG
          0_CD ._. 02_CD %_NN DEPC_NNP ,_, snap_NN frozen_VBN ,_, and_CC stored_VBD at_IN -_: 70_CD °_NN C_NNP ._. Clontech_NNP
          (_( Clontech_NNP Laboratories_NNPS ,_, Inc_NNP ._. ,_, Palo_NNP Alto_NNP ,_, CA_NNP )_) Mouse_NNP 1_CD ._. 2_CD
          cDNA_NN Expression_NNP Arrays_NNP were_VBD used_VBN to_TO analyze_VB each_DT sample_NN ._.
          These_DT arrays_NNS include_VBP 1176_CD mouse_NN cDNAs_NNS ,_, 9_CD housekeeping_NN
          control_NN cDNAs_NNS ,_, and_CC negative_JJ controls_NNS immobilized_JJ on_IN a_DT
          nylon_NN membrane_NN www_NN ._. clontech_NN ._. com_NN ._. Briefly_NNP ,_, total_JJ RNA_NNP was_VBD
          isolated_VBN and_CC cDNA_NN probes_NNS were_VBD synthesized_JJ using_VBG the_DT Atlas_NNP
          Pure_NNP Total_NNP RNA_NNP Labeling_VBG System_NNP and_CC 32_CD P_NN ._. The_DT labeled_VBN cDNA_NN
          probes_NNS were_VBD hybridized_JJ to_TO the_DT Atlas_NNP Array_NNP using_VBG
          ExpressHyb_NNP Solution_NN ._. Hybridization_NNP signals_NNS were_VBD revealed_VBN
          by_IN phosphorimaging_VBG and_CC quantitated_JJ using_VBG the_DT Clontech_NNP
          Atlas_NNP Image_NN 1_CD ._. 01_CD software_NN package_NN ,_, which_WDT allows_VBZ for_IN
          unbiased_JJ normalization_NN of_IN transcript_NN abundance_NN to_TO overall_JJ
          signal_NN ._. We_PRP generated_VBD pseudocolored_JJ images_NNS indicating_VBG up_RP
          and_CC down_RB gene_NN regulation_NN ._. The_DT probe_NN set_VBD intensity_NN
          (_( average_JJ difference_NN )_) is_VBZ proportional_JJ to_TO the_DT abundance_NN of_IN
          the_DT specific_JJ mRNA_NN it_PRP represents_VBZ and_CC was_VBD calculated_VBN by_IN
          comparing_VBG hybridization_NN signal_NN of_IN the_DT control_NN
          oligonucleotide_NN to_TO that_DT of_IN the_DT treated_VBN ._. Total_JJ signal_NN
          intensity_NN of_IN different_JJ probes_NNS was_VBD scaled_VBN to_TO the_DT same_JJ
          value_NN before_IN comparison_NN ._. Fold_NNP changes_NNS were_VBD calculated_VBN by_IN
          AtlasImage_NNP 1_CD ._. 0_CD software_NN by_IN pair-wise_JJ comparisons_NNS of_IN
          corresponding_JJ probe_NN pairs_NNS from_IN experimental_JJ and_CC control_NN ._.
          Three_CD independent_JJ experiments_NNS were_VBD conducted_VBN per_IN
          experimental_JJ group_NN and_CC the_DT composite_JJ array_NN determined_VBN ._.
          Relevant_NNP genes_NNS with_IN altered_VBN expression_NN were_VBD then_RB assigned_VBN
          to_TO functional_JJ groups_NNS ._. Specifically_RB ,_, we_PRP assigned_VBN those_DT
          genes_NNS related_VBN to_TO the_DT 
          Connections_NNP Map_NNP (_( Fig_NNP ._. 1_LS )_) that_WDT have_VBP
          a_DT 1_CD ._. 5_CD or_CC greater_JJR fold-change_JJ to_TO functional_JJ groups_NNS (_( 
          i_NNP ._. e_SYM ._. ,_, cell_NN cycle_NN ,_, apoptosis_NNS ,_, signal_NN
          transduction_NN ,_, etc_FW ._. )_) which_WDT have_VBP biological_JJ
          significance_NN ._.
        
        
          2_LS -_: D_NNP western_JJ array_NN screening_NN
          The_DT expression_NN of_IN signaling_VBG proteins_NNS was_VBD analyzed_VBN by_IN
          Powerblot_NNP Western_NNP Array_NNP Screening_NNP (_( BD_NNP Transduction_NNP
          Laboratories_NNPS ,_, Lexington_NNP ,_, KY_NNP )_) ._. This_DT 2_CD -_: D_NNP Western_NNP Blot_NNP Array_NNP
          methodology_NN simultaneously_RB examines_VBZ relative_JJ changes_NNS in_IN
          protein_NN expression_NN in_IN ~_NN 600_CD proteins_NNS in_IN a_DT given_VBN sample_NN ._.
          Using_VBG highly_RB specific_JJ monoclonal_NN antibodies_NNS in_IN antibody_NN
          combinations_NNS carefully_RB formulated_VBN by_IN BD_NNP Transduction_NNP
          Laboratories_NNPS ,_, this_DT multiprotein_NN assay_NN detects_NNS proteins_NNS to_TO
          the_DT nanogram_NN levels_NNS and_CC can_MD distinguish_VB closely_RB related_VBN
          members_NNS of_IN many_JJ important_JJ signaling_VBG families_NNS ._. E_NNP 15_CD +_NN 2_CD CONT_NNP
          and_CC SN_NNP 50_CD -_: treated_VBN explants_NNS were_VBD collected_VBN and_CC processed_VBN
          according_VBG to_TO the_DT protocol_NN of_IN BD_NNP Transduction_NNP
          Laboratories_NNPS ._. Each_DT sample_NN (_( CONT_NNP and_CC SN_NNP 50_CD -_: treated_VBN )_) was_VBD
          analyzed_VBN on_IN 4_CD separate_JJ 2_CD -_: D_NNP gels_NNS which_WDT were_VBD then_RB
          transferred_VBN onto_IN 4_CD blots_NNS ._. Each_DT blot_NN was_VBD then_RB incubated_JJ
          with_IN a_DT different_JJ mixture_NN of_IN ~_NN 150_CD monoclonal_NN antibodies_NNS
          and_CC proteins_NNS were_VBD detected_VBN by_IN chemiluminescence_NN ;_: ~_NN 600_CD
          (_( 150_CD antibodies_NNS ×_NN 4_CD blots_NNS )_) proteins_NNS were_VBD evaluated_VBN in_IN a_DT
          given_VBN sample_NN ._. For_IN this_DT set_JJ of_IN experiments_NNS ,_, two_CD
          independent_JJ samples_NNS were_VBD analyzed_VBN The_DT relative_JJ level_NN of_IN
          proteins_NNS were_VBD determined_VBN by_IN phosphor_NN imaging_NN and_CC
          normalized_JJ to_TO overall_JJ signal_NN ._. We_PRP then_RB assigned_VBN those_DT 
          Connections_NNP Map_NNP proteins_NNS with_IN a_DT 1_CD ._. 5_CD
          or_CC greater_JJR fold-change_JJ to_TO functional_JJ groups_NNS as_IN described_VBN
          above_IN ._.
        
        
          1_LS -_: D_NNP western_JJ blot_NN analysis_NN
          To_TO determine_VB which_WDT key_JJ pathways_NNS were_VBD activated_VBN ,_,
          Western_JJ blot_NN analyses_NNS of_IN phosphorylated_JJ or_CC cleaved_JJ
          proteins_NNS in_IN E_NNP 15_CD +_NN 2_CD CONT_NNP and_CC SN_NNP 50_CD -_: treated_VBN explants_NNS were_VBD
          conducted_VBN as_RB previously_RB described_VBD [_NN 5_CD ]_NN ._. For_IN this_DT set_JJ of_IN
          experiments_NNS ,_, we_PRP first_RB determined_VBD the_DT specificity_NN for_IN each_DT
          of_IN the_DT following_VBG antibodies_NNS purchased_VBN from_IN Cell_NNP Signaling_NNP
          Technology_NNP (_( Beverly_NNP ,_, MA_NNP )_) using_VBG E_NNP 15_CD and_CC E_NNP 17_CD SMG_NNP
          homogenates_NNS :_: anti-phosphorylated_JJ Erk_NNP 1_CD /_NN 2_CD [_NN phospho-p_JJ 44_CD /_NN 42_CD
          MAP_NNP kinase_NN (_( Thr_NNP 202_CD /_NN Tyr_NNP 204_CD )_) ]_NN antibody_NN ,_, anti-phosphorylated_JJ
          c-_NN Raf_NNP (_( Ser_NNP 259_CD )_) antibody_NN ,_, anti-cleaved_JJ Caspase_NNP 3_CD (_( D_NNP 175_CD )_)
          antibody_NN ,_, and_CC anti-cleaved_JJ PARP_NNP (_( D_NNP 214_CD )_) antibody_NN ._. Each_DT
          antibody_NN had_VBD previously_RB been_VBN shown_VBN to_TO be_VB specific_JJ for_IN the_DT
          activated_VBN (_( phosphorylated_JJ /_NN cleaved_JJ )_) protein_NN and_CC not_RB to_TO
          cross_VB react_VB with_IN inactive_JJ protein_NN ._. Once_RB optimal_NN
          experimental_JJ conditions_NNS were_VBD established_VBN for_IN each_DT
          antibody_NN ,_, we_PRP then_RB incubated_JJ blots_NNS of_IN E_NNP 15_CD and_CC E_NNP 17_CD SMGs_NNP in_IN
          a_DT mixture_NN of_IN these_DT 4_CD antibodies_NNS and_CC determined_VBN that_IN we_PRP
          could_MD identify_VB all_DT proteins_NNS in_IN a_DT single_JJ sample_NN by_IN M_NNP 
          r_LS ._. This_DT methodology_NN using_VBG a_DT mixture_NN
          of_IN antibodies_NNS has_VBZ been_VBN successfully_RB used_VBN by_IN Cell_NNP
          Signaling_NNP Technology_NNP and_CC BD_NNP Signal_NNP Transduction_NNP for_IN 2_CD -_: D_NNP
          and_CC 1_CD -_: D_NNP Western_JJ blot_NN analyses_NNS ._. Controls_NNP consisted_VBD of_IN
          blots_NNS incubated_JJ in_IN preimmune_NN rabbit_NN serum_NN or_CC in_IN the_DT
          absence_NN of_IN primary_JJ antibodies_NNS ;_: controls_NNS were_VBD routinely_RB
          negative_JJ ._. In_IN each_DT sample_NN ,_, each_DT 
          activated_VBN protein_NN was_VBD identified_VBN by_IN
          M_NNP 
          r_LS and_CC the_DT relative_JJ level_NN of_IN 
          activated_VBN proteins_NNS in_IN CONT_NNP and_CC
          SN_NNP 50_CD -_: treated_VBN explants_NNS was_VBD determined_VBN by_IN densitometry_NN ._. The_DT
          SN_NNP 50_CD results_NNS are_VBP presented_VBN as_IN fold_VB change_NN relative_JJ to_TO
          CONT_NNP protein_NN ._. Two_CD independent_JJ samples_NNS per_IN group_NN was_VBD
          analyzed_VBN ._. Statistical_NNP comparisons_NNS were_VBD made_VBN between_IN CONT_NNP
          and_CC SN_NNP 50_CD -_: treated_VBN E_NNP 15_CD +_NN 2_CD explants_NNS as_IN described_VBN below_IN ._.
        
        
          Probabilistic_NNP neural_NN network_NN analysis_NN
          We_PRP used_VBD PNN_NNP analyses_NNS to_TO determine_VB which_WDT 
          Connection_NN Map_NNP (_( Fig_NNP ._. 1_LS )_) transcripts_NNS
          or_CC proteins_NNS with_IN altered_VBN expression_NN best_JJS discriminate_JJ
          CONT_NNP from_IN SN_NNP 50_CD -_: treated_VBN explants_NNS with_IN 100_CD %_NN sensitivity_NN and_CC
          specificity_NN [_NN 69_CD ]_NN ._. PNN_NNP analyses_NNS identify_VBP the_DT relative_JJ
          importance_NN (_( 0_CD -_: 1_CD ,_, with_IN 0_CD being_NN of_IN no_DT relative_JJ importance_NN
          and_CC 1_CD being_VBG relatively_RB most_RBS important_JJ )_) of_IN gene_NN and_CC
          protein_NN expression_NN changes_NNS in_IN defining_VBG the_DT SN_NNP 50_CD
          phenotype_NN ._. It_PRP is_VBZ the_DT change_NN in_IN expression_NN ,_, not_RB the_DT
          direction_NN of_IN change_NN ,_, that_WDT is_VBZ important_JJ in_IN defining_VBG the_DT
          phenotype_NN ._. The_DT algorithm_NN we_PRP used_VBD (_( Ward_NNP Systems_NNPS Group_NNP ,_,
          Frederick_NNP ,_, MD_NNP )_) is_VBZ based_VBN upon_IN the_DT work_NN of_IN Specht_NNP and_CC
          colleagues_NNS [_NN 69_CD 70_CD 71_CD 72_CD ]_NN ._. Utilizing_NNP proprietary_JJ
          software_NN designed_VBN by_IN Ward_NNP Systems_NNPS Group_NNP (_( Frederick_NNP ,_, MD_NNP )_) ,_,
          we_PRP made_VBD comparisons_NNS among_IN 
          Connections_NNP Map_NNP transcripts_NNS or_CC
          proteins_NNS with_IN altered_VBN expression_NN in_IN a_DT given_VBN group_NN ._.
        
        
          Statistical_NNP analysis_NN
          Means_NNP differences_NNS were_VBD analyzed_VBN by_IN t-test_JJ in_IN the_DT usual_JJ
          manner_NN [_NN 73_CD ]_NN ._. To_TO meet_VB the_DT assumptions_NNS of_IN this_DT analysis_NN ,_,
          namely_RB normality_NN and_CC homoscedasticity_NN (_( homogeneity_NN of_IN
          variances_NNS )_) ,_, counts_VBZ ,_, ratios_NNS ,_, and_CC percentages_NNS were_VBD log_VB or_CC
          arcsin_NN transformed_VBD [_NN 74_CD ]_NN ._. This_DT allows_VBZ for_IN parametric_JJ
          statistical_JJ testing_NN ._.
        
      
    
  
